About Precipio Diagnostics
Precipio Diagnostics is a publicly listed company based in New Haven (United States) founded in 1997. Cancer diagnostics and second opinion tools are offered. The company has 60 employees. Precipio Diagnostics offers products and services including Molecular Kits, IV-Cell Culture Media, and Hematopathology Services. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Blood Cancer. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Provider of cancer diagnostics and second opinion tools. The company uses ICE COLD-PCR technology to detect cancer mutations. The product includes SmartGen is a combination of diagnostic tools for the prognosis and diagnosis of cancer. SmartPath is a service that couples the patient and treating physician, with an academic expert for a second opinion. Results are generally provided within hours and customers can also request a live consultation with the pathologist. It also provides a HemeScreen Panel for screening hematologic malignancy.
- Headquarters New Haven, United States
- Employees 60
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website precipiodx.com
- Social LinkedIn Facebook YouTube
- Legal Name Precipio, Inc.
- Annual Revenue$24.05 M (USD)29.77as on Dec 31, 2025
- Net Profit-$363 K (USD)91.54as on Dec 31, 2025
- EBITDA$550 K (USD)as on Dec 31, 2025
- Latest Funding Round$810.84K (USD), Post-IPO
Oct 2017
- InvestorsEnhanced Capital
& 3 more
- Employee Count60
Products & Services of Precipio Diagnostics
Precipio Diagnostics offers a comprehensive portfolio of products and services, including Molecular Kits, IV-Cell Culture Media, and Hematopathology Services.
Kits for detecting driver mutations in blood cancers
Media for multi-cell lineage culturing in diagnostics
Diagnostic testing for accurate blood cancer analysis
Apps and channels of Precipio Diagnostics
its YouTube channel PrecipioDX has 38 subscribers and 12 videos.
Videos from Precipio Diagnostics
The most watched videos on Precipio Diagnostics's YouTube channel, PrecipioDX (38 subscribers). Click a video to play it here.
More on PrecipioDX.
Funding Insights of Precipio Diagnostics
- Total Rounds 5
- Last Round Post-IPO — $810,840
- First Round $1.08M
(Oct 2011)
- Investors Count 4
All 5 funding rounds of Precipio Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $810,840 | Post-IPO | – | – | – |
| Jun 2017 | $800,000 | Debt – Convertible | – | – | – |
| Jun 2017 | $399,997 | Post-IPO | – | – | – |
| Oct 2013 | $1.8M | Post-IPO | – | – | |
| Oct 2011 | $1.08M | Post-IPO | – | – | – |
4 investors in total: 4 institutional.
Investors in Precipio Diagnostics
Precipio Diagnostics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Enhanced Capital, Connecticut Innovations and Ironwood Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
Private equity and debt investments are focused on multiple sectors. | ironwoodcap.com | Avon, United States | ||
A capital access and managed service platform is provided. | kuzarigroup.com | |||
Venture debt is provided to early-stage US companies. | 1999 | enhancedcapital.com | New York, United States |
Investor details for Precipio Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Precipio Diagnostics
24 people are tracked at Precipio Diagnostics (7 in leadership, 6 in board & advisors, 11 in team); the tracked headcount is 60.
| Name | Role | Group |
|---|---|---|
Ayman Mohamed | CTO | Leadership |
A. Zaki Sabet | COO | Leadership |
Ilan Danieli | CEO | Leadership |
Matthew Gage | Interim CFO | Leadership |
Miri Chiko-Radomski | Chief Legal Counsel & People Officer | Leadership |
S. David Hudnall | Medical Director | Leadership |
Mehmed Iljazi | Vp, Administrative Operations | Leadership |
Jeffrey Cossman | Director | Board & advisors |
Kathy Laporte | Director | Board & advisors |
Doug Fisher | Director | Board & advisors |
Ron A. Andrews | Director | Board & advisors |
David S. Cohen | Director | Board & advisors |
Richard Sandberg | Chairman Of The Board | Board & advisors |
Keith Meadors | SVP, Products Division | Team |
Allison Brownell | Clinical Oncology Specialist | Team |
Michelle Scully | Laboratory Manager | Team |
Gulten Iljazi | Project Manager, Lab Information System (lis) | Team |
Heather Newell | Research And Development Scientist | Team |
Stephanie Ferro | Laboratory Manager | Team |
Kaleigh S. | Laboratory & Logistics Manager | Team |
4 more people are available in the full profile.
Complete people profiles for Precipio Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Precipio Diagnostics
Precipio Diagnostics is a publicly listed company on the NASDAQ with ticker symbol PRPO in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Oct 2014
- Listed onNASDAQ: PRPO
- Listed entityPrecipio, Inc.
- Exchange sectorHealth services
- ISINUS74019L6020
- Share price$22.59 · 2026-10-13
- Market capitalisation$40.4M
- EPS (diluted, trailing year)$-0.68
- Volume (last session)29,986
Financials of Precipio Diagnostics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $24.1M | -$363,000 | $550,000 |
| 2024 | $18.5M | -$4.3M | -$2.7M |
| 2023 | $15.2M | -$5.8M | -$6.1M |
| 2022 | $9.4M | -$12.2M | -$11.3M |
| 2021 | $8.8M | -$8.5M | -$8.2M |
Detailed financial statements for Precipio Diagnostics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Precipio Diagnostics
4 dated milestones of Precipio Diagnostics across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Precipio Diagnostics is founded.
- Funding First funding round of $1.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $811K.
Competitors of Precipio Diagnostics
Precipio Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of Precipio Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Precipio Diagnostics
The website of Precipio Diagnostics (precipiodx.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▲ 5.7% vs previous month
Websites whose visitors overlap most with Precipio Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| manta.com | 100% | 1.1M | #48,924 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Precipio Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Precipio Diagnostics
Complete news archive for Precipio Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Precipio Diagnostics
Precipio Diagnostics was founded in 1997 and raised its 1st funding round 14 years after it was founded.
Precipio Diagnostics is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Precipio Diagnostics has 60 employees.
Annual revenue of Precipio Diagnostics is $24.05M as on Dec 31, 2025.
Provider of cancer diagnostics and second opinion tools. The company uses ICE COLD-PCR technology to detect cancer mutations. The product includes SmartGen is a combination of diagnostic tools for the prognosis and diagnosis of cancer. SmartPath is a service that couples the patient and treating physician, with an academic expert for a second opinion. Results are generally provided within hours and customers can also request a live consultation with the pathologist. It also provides a HemeScreen Panel for screening hematologic malignancy.
Precipio Diagnostics's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
Precipio Diagnostics offers Molecular Kits, IV-Cell Culture Media, and Hematopathology Services.
Yes, Precipio Diagnostics is publicly traded on NASDAQ under the ticker symbol PRPO.
Precipio Diagnostics has 4 investors. Key investors include Enhanced Capital, Connecticut Innovations, Ironwood Capital, and Kuzari.